The Science of Metabolic Peptide Therapy
The metabolic peptide landscape has transformed dramatically with the advent of GLP-1 receptor agonists and dual/triple agonist therapies. This hub covers the mechanisms, clinical evidence, and practical considerations for peptides that influence body composition, appetite regulation, insulin sensitivity, and overall metabolic health.
Featured Topics
- GLP-1 receptor agonists: semaglutide, tirzepatide, retatrutide mechanisms and clinical data
- Fat-loss fragments: AOD 9604, HGH Fragment 176-191, and adipotide research
- Mitochondrial peptides: MOTS-c and 5-Amino-1MQ for metabolic performance
- Appetite regulation: tesofensine and cagrilintide mechanisms
- Peptide stacking strategies for metabolic optimization
From GLP-1 Agonists to Triple Agonists
The evolution from single-target GLP-1 agonists like semaglutide to dual (tirzepatide) and triple (retatrutide) agonists represents one of the most significant advances in metabolic medicine. These peptides work by mimicking incretin hormones, enhancing insulin secretion, slowing gastric emptying, and acting on central appetite centers.
Beyond the headline-grabbing weight loss results, metabolic peptides show promise for reducing visceral adiposity, improving insulin resistance, managing PCOS symptoms, and potentially addressing metabolic syndrome as a whole. Our articles examine the evidence behind each peptide, proper dosing considerations, and what the research actually shows.
